CONTEXT: Autoantibodies to 21-hydroxylase (21OH-AA) precede onset of autoimmune Addison's disease (AD). Progression to AD can take months to years, and early detection of metabolic decompensation may prevent morbidity and mortality. OBJECTIVE: To define optimal methods of predicting progression to overt AD (defined by subnormal peak cortisol response to Cosyntropin) in 21OH-AA+ individuals. DESIGN, SETTING AND PARTICIPANTS: Individuals were screened for 21OH-AA at the Barbara Davis Center from 1993 to 2011. Subjects positive for 21OH-AA (n = 87) were tested, and the majority prospectively followed for the development of Addison's disease, including seven diagnosed with AD upon 21OH-AA discovery (discovered), seven who progressed to AD (progressors) and 73 nonprogressors. MAIN OUTCOME MEASURED: Plasma renin activity (PRA), ACTH, baseline cortisol, peak cortisol and 21OH-AA were measured at various time points relative to diagnosis of AD or last AD-free follow-up. RESULTS: Compared with nonprogressors, in the time period 2 months-2 years prior to the onset of AD, progressors were significantly more likely to have elevated ACTH (11-22 pM, P < 1E-4), with no significant differences in mean PRA (P = 0·07) or baseline cortisol (P = 0·08), and significant but less distinct differences seen with 21OH-AA levels (P < 1E-4) and poststimulation cortisol levels (P = 6E-3). CONCLUSION: Moderately elevated ACTH is a more useful early indicator of impending AD than 21OH-AA, PRA or peak cortisol, in the 2 months-2 years preceding the onset of AD.
CONTEXT: Autoantibodies to 21-hydroxylase (21OH-AA) precede onset of autoimmune Addison's disease (AD). Progression to AD can take months to years, and early detection of metabolic decompensation may prevent morbidity and mortality. OBJECTIVE: To define optimal methods of predicting progression to overt AD (defined by subnormal peak cortisol response to Cosyntropin) in 21OH-AA+ individuals. DESIGN, SETTING AND PARTICIPANTS: Individuals were screened for 21OH-AA at the Barbara Davis Center from 1993 to 2011. Subjects positive for 21OH-AA (n = 87) were tested, and the majority prospectively followed for the development of Addison's disease, including seven diagnosed with AD upon 21OH-AA discovery (discovered), seven who progressed to AD (progressors) and 73 nonprogressors. MAIN OUTCOME MEASURED: Plasma renin activity (PRA), ACTH, baseline cortisol, peak cortisol and 21OH-AA were measured at various time points relative to diagnosis of AD or last AD-free follow-up. RESULTS: Compared with nonprogressors, in the time period 2 months-2 years prior to the onset of AD, progressors were significantly more likely to have elevated ACTH (11-22 pM, P < 1E-4), with no significant differences in mean PRA (P = 0·07) or baseline cortisol (P = 0·08), and significant but less distinct differences seen with 21OH-AA levels (P < 1E-4) and poststimulation cortisol levels (P = 6E-3). CONCLUSION: Moderately elevated ACTH is a more useful early indicator of impending AD than 21OH-AA, PRA or peak cortisol, in the 2 months-2 years preceding the onset of AD.
Authors: C Betterle; M Volpato; B Rees Smith; J Furmaniak; S Chen; N A Greggio; M Sanzari; F Tedesco; B Pedini; M Boscaro; F Presotto Journal: J Clin Endocrinol Metab Date: 1997-03 Impact factor: 5.958
Authors: G Gambelunghe; A Falorni; M Ghaderi; S Laureti; C Tortoioli; F Santeusanio; P Brunetti; C B Sanjeevi Journal: J Clin Endocrinol Metab Date: 1999-10 Impact factor: 5.958
Authors: Peter R Baker; Erin E Baschal; Pam R Fain; Taylor M Triolo; Priyaanka Nanduri; Janet C Siebert; Taylor K Armstrong; Sunanda R Babu; Marian J Rewers; Peter A Gottlieb; Jennifer M Barker; George S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2010-07-14 Impact factor: 5.958
Authors: K Badenhoop; P G Walfish; H Rau; S Fischer; A Nicolay; U Bogner; H Schleusener; K H Usadel Journal: J Clin Endocrinol Metab Date: 1995-07 Impact factor: 5.958
Authors: Z Gombos; R Hermann; M Kiviniemi; S Nejentsev; K Reimand; V Fadeyev; P Peterson; R Uibo; J Ilonen Journal: Eur J Endocrinol Date: 2007-12 Impact factor: 6.664
Authors: S Laureti; P Aubourg; F Calcinaro; F Rocchiccioli; G Casucci; G Angeletti; P Brunetti; A Lernmark; F Santeusanio; A Falorni Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: S Laureti; A De Bellis; V I Muccitelli; F Calcinaro; A Bizzarro; R Rossi; A Bellastella; F Santeusanio; A Falorni Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: Kristen M Williams; Pamela Fazzio; Sharon E Oberfield; Mary P Gallagher; Gaya S Aranoff Journal: Clin Pediatr (Phila) Date: 2017-02 Impact factor: 1.168